Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases
−ACERCA DE LA PORTADA−  El virus Epstein-Barr (EBV) es un gamma herpes virus que afecta humanos. La infección se adquiere principalmente durante la infancia o adolescencia; se presenta de manera asintomática o como un trastorno linfoproliferativo autolimitado que no requiere atención clínica. Sin embargo, afecta a más del 95% de la población adulta mundial y corresponde a uno de los virus oncogénicos más comunes en la especie humana: en promedio, cada año se asocia con 200,000 casos de cáncer. Interesantemente, solo un pequeño porcentaje de individuos infectados desarrolla procesos malignos, normalmente hospederos inmunocomprometidos o inmunodeficientes. EBV tiene un tropismo casi exclusivo por células B y de manera general la infección conduce a un estado latente o lítico, a partir de los cuales es posible desarrollar enfermedades y complicaciones. Las células citotóxicas NK y T CD8+ son los principales agentes inmunológicos que controlan y eliminan la infección por EBV. En este contexto, variantes genéticas que comprometan el desarrollo, proliferación, diferenciación, coestimulación y/o activación de células NK y T CD8+ predisponen al desarrollo de neoplasias o trastornos linfoproliferativos. Específicamente, se ha descrito la deficiencia, haploinsuficiencia o desregulación de ciertas proteínas citoplasmáticas, receptores de membrana, ligandos y transportadores de iones que afectan la función efectora de las células citotóxicas, y resultan en las secuelas más graves por EBV. Sin duda, el conocimiento ganado en este tema seguirá contribuyendo a diagnósticos más oportunos y el desarrollo de mejores estrategias terapéuticas en la clínica.     Breve descripción de la portada: Dres. Arturo Gutiérrez Guerrero, Sara Elva Espinosa Padilla y Saúl Oswaldo Lugo Reyes.   Agradecimiento especial por la elaboración y diseño de la portada: DG. Diana Gabriela Salazar Rodríguez.
PDF
XML

Palabras clave

Asthma
Burden of the disease
Costs
Economic burden

Cómo citar

Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases. (2024). Revista Alergia México, 71(1), 12-22. https://doi.org/10.29262/ram.v71i1.1279

Datos de los fondos

Plaudit

Resumen

Objective: Determine the annual economic burden of the disease from an institutional perspective and based on GINA’s recommended classification in a retrospective cohort of adults treated at Instituto Nacional de Enfermedades Respiratorias (INER) of Mexico City.

Methods: A retrospective, longitudinal observational study comprised by data from 247 female asthma patients, annual direct costs were estimated including: visits, laboratory tests, pharmacological treatment and management of crisis or exacerbations, to determine the annual burden of the disease from an institutional perspective and according to Global Initiative for Asthma classification.

Results: The average annual cost was $43,813.92, which increased in relation to the need of inhaled corticosteroids and long-acting beta agonists dosage increase. The average doctor’s appointment cost was $2,004.57, $982.82 for crisis management and $2,645.95 for laboratory testing. Pharmacological treatment represented the main economic burden with an annual average cost of $38,180.58.

Conclusions: The results highlight an economic burden of asthma estimated at an annual cost per patient of $43,813.92 MXN (SD=93,348.85) in the context of the third level of care in the Mexican public health system. The asthma severity and treatments such as biologics were the main factors that increased direct costs of care.

PDF
XML

Referencias

World Health Organization Asthma Fact Sheet. https://www.who.int. [Online].; 2021 [cited 2021 Nov 02. Available from: https://www.who.int/es/news-room/fact-sheets/detail/asthma.

Del-Río-Navarro B, Berber A, Reyes-Noriega N, Navarrete-Rodríguez E, García-Almaraz R, Ellwood P, et al. Global Asthma Network Phase I study in Mexico: prevalence of asthma symptoms, risk factors and altitude associations-a cross-sectional study. BMJ Open Respir Res. 2020 Dec; 7(1): p. e000658.

Flórez-Tanus Á, Parra D, Zakzuk J, Caraballo L, Alvis-Guzmán N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018 Nov; 11(1).

Mexico’s Health Department. Morbidity Yearbook 1984 - 2019. 2021 https://epidemiologia.salud.gob.mx/anuario/html/morbilidad_nacional.html. Accessed 5th of November 2021. [Text in Spanish]

Ocampo J GRSJ. Prevalence of asthma in Latin America. Critical look at ISAAC and other studies. Rev Alerg Mex. 2017 Apr-Jun; 64(2): 188-197. [Text in Spanish]

Global Initiative for Asthma. 2021 https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/. Accessed 5th of November 2021.

Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002 Jan; 19(1): 61-67.

World Health Organization. WHO. 2021 https://www.who.int/publications/i/item/who-2019-ncov-sci-brief-asthma-2021.1. Accessed 5th of November 2021.

AGREEMENT number ACDO.AS3.HCT.301120/310.P.DF dictated by the H. Technical Council on their ordinary session on November 30th of 2020, related to the approval of Unitary Costs by Level updated to the year 2021. Official Federation Diary. 28th of December of 2020 [Text in Spanish]

Janson C, Lisspers K, Ställberg B, Johansson G, Telg G, Thuresson M, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). Respir Res. 2018 Sep; 19(1): p. 168.

Glick, Henry A. and others, Economic Evaluation in Clinical Trials, 2 edn, Handbooks in Health Economic Evaluation (Oxford, 2014; online edn, Oxford Academic, 1 Oct. 2014), https://doi.org/10.1093/med/9780199685028.001.0001 Accessed on April 29th 2022.

Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009 May 19;9:24.

Fernández-Vega Margarita, Vargas Mario H., Regalado-Pineda Justino, Chapela-Mendoza Rocío, Salas-Hernández Jorge. Characteristics of the Mexican asthma patient in outpatient clinics. Rev. invest. Clín. 57(4), 513-521. [Text in Spanish]

Mexico’s Superior Audit Department. Performance of Mexico´s National Institute of Respiratory Diseases Ismael Cosío Villegas. Performance audit 2018-1-12NCD-07-1590-2019. 1590-DS. https://www.asf.gob.mx/Trans/Informes/IR2020c/Documentos/Auditorias/2020_0248_a.pdf Accessed 5th of November 2021. [Text in Spanish]

National Institute for Respiratory Diseases. Budget Reports. http://iner.salud.gob.mx/interna/armonizacioncontable_informacionpresupuestal.html. Accessed 5th of November 2021. [Text in Spanish]

Martínez-Moragón E, Climent M, Chiner E, Fernández-Aracil C, Sánchez-Toril F, Lluch-Tortajada I; Effectivenes and pharmacoeconomic analysis of severe asthma treated with omalizumab in the clinical practice.Farm Hosp. 2019;43:101-9. [Text in Spanish]

Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG, Padilla-Galo A, Levy A, Álvarez-Gutiérrez FJ, et al. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. Pharmacoecon Open 2019; 3:333-42

Zein JG, Erzurum SC. Asthma is Different in Women. Curr Allergy Asthma Rep. 2015 Jun;15(6):28.

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.

Derechos de autor 2023 Revista Alergia México

Downloads

Download data is not yet available.